Reha Rheinfelden
Rheinfelden, Canton of Aargau, 4310, Switzerland
NCT Number: NCT03598101
The importance of physical activity and exercise-based interventions in neuro-orthopaedic rehabilitation is undisputed. Yet, patients and clinicians do not implement minimally required doses of physical activity in standard rehabilitation programs. This is partly due to intrinsic factors such as motivation, or due to physical condition that prevent any kind of exercise. In most cases, however, it is owed to limited time spent with therapists who would be able to supervise and apply the required doses to induce any potential exercise effects. Methods to semi-autonomously exercise with high motivation and continuous feedback would complement existing therapies and allow adherence to minimal dose recommendations.
For this study, a prototype of a new portable training solution for intensive walking exercise with built-in sensor-technology and a smartphone interface will be tested regarding its usability and its efficiency in a clinical setting.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Rheinfelden, Canton of Aargau, 4310, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
Time frame: 3-4 weeks
Participants will be asked to rate the perceived usability based on the System Usability Scale (SUS). SUS assesses perceived effectiveness (can users successfully achieve their objectives), information quality (how much effort and resource is expended in achieving those objectives) and general satisfaction (was the experience satisfactory). The SUS hast 10 items that can be rated on a 5-point likert scale. The items will be scored as follows:
Time frame: 3-4 weeks
Each participant will have a list of tasks to be completed per session. Amount of additional assistance following the introduction (after three supervised sessions), will be counted as outcome. E.g. additional verbal cues or practical assistance.
Time frame: 3-4 weeks
Each participant will have a list of tasks to be completed per session. mean completion rate/mean task time = completion rate efficiency [%/s]; e.g. 80% completed all tasks within an average of 360 seconds.
Task time: mean time taken before training was started [s].
Time frame: 3-4 weeks
Each participant will have a list of tasks to be completed per session. mean goal achievement/mean task time = Goal achievement efficiency [%/s]; e.g. 43% completed in 360 seconds Mean goal achievement: Mean extent to which the tasks were completed [%], e.g. 3 out of 7 tasks completed correctly = 43%.
Time frame: At first visit (t+0) and prior to first training 2-4 days after first vist (t+2)
Standardised clinical assessment often employed as part of routine assessments will be used. The 10 Meter Walk Test (10MWT) is a performance measure used to assess walking speed in meters per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function.
Time frame: At first visit (t+0) and prior to first training 2-4 days after first vist (t+2)
A second standardised clinical assessment often employed as part of routine assessments will be used. The 6 Minute Walk Test (6MWT) is a sub-maximal exercise test used to assess aerobic capacity and endurance.
Time frame: At first visit (t+0 days) and prior to first training 2-4 days after first vist (t+2 days)
Cardiopulmonary response will be measured using a breath-by-breath cardiorespiratory monitoring system (MetaMax 3B, Cortex Biophysik, Leipzig, Germany) and a receiver board (HRMI, Sparkfun, Boulder, USA). During 10 meter walk test and a 6-minute walk test, oxygen uptake (VO2) and carbon dioxide output (VCO2) will be recorded and reported and VCO2/VO2 relationship.
Time frame: At first visit (t+0 days) and prior to first training 2-4 days after first vist (t+2 days)
During 10 meter walk test and a 6-minute walk test, heart rate (HR) will be recorded in both conditions (with and without belt). HR will be recorded over a rate belt (T31, Polar Electro, Kempele, Finland).
Time frame: At first visit (t+0 days).
The amount of experience with walking exercise (qualitative, verbal description or as hours/week, if applicable),
Time frame: At first visit (t+0 days).
Time frame: At first visit (t+0 days).
Age in years.
Time frame: At first visit (t+0 days).
Weight [kg] and height [m] in BMI [kg/m^2]
Time frame: At first visit (t+0 days).
Profession (qualitative description)
Time frame: 3 to 4 weeks after first visit.
For attrition, the number of participants lost during the intervention was recorded. For adherence, participants' engagement with the intervention will be assessed.
Time frame: 3 to 4 weeks after first visit.
Adherence will be calculated as the number of completed training sessions as a percentage of the maximal possible training sessions.
Time frame: 3-4 weeks
Training duration and intensity will be derived from the smartphone interface.
Reha Rheinfelden
Other
TONEFITreha: Proof of Concept and Usability of a Portable Exercise Device to Improve Cardiovascular Functioning and Balance in Neuro-orthopaedic Rehabilitation.
Acronym: TONFITreha
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03490539
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Palo Alto, California, United States
View Trial DetailsNCT06352372
Autism Spectrum Disorder, Autistic Disorder
Phoenix, Arizona, United States
View Trial DetailsNCT05938452
Nervous System Diseases, Neurological Disorder
Bloomfield, New Jersey, United States
View Trial DetailsNCT05493397
Nervous System Diseases, Neurological Disorder
London, United Kingdom
View Trial Details